Cytomx Therapeutics Stock Market Value
| CTMX Stock | USD 5.67 0.43 8.21% |
| Symbol | CytomX |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytomX Therapeutics. Projected growth potential of CytomX fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive CytomX Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.606 | Earnings Share 0.3 | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets |
CytomX Therapeutics's market price often diverges from its book value, the accounting figure shown on CytomX's balance sheet. Smart investors calculate CytomX Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since CytomX Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between CytomX Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding CytomX Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, CytomX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
CytomX Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CytomX Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CytomX Therapeutics.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in CytomX Therapeutics on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding CytomX Therapeutics or generate 0.0% return on investment in CytomX Therapeutics over 90 days. CytomX Therapeutics is related to or competes with Erasca, Iovance Biotherapeutics, MBX Biosciences, ArriVent BioPharma, MeiraGTx Holdings, MoonLake Immunotherapeuti, and Replimune. CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States More
CytomX Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CytomX Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CytomX Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.91 | |||
| Information Ratio | 0.1075 | |||
| Maximum Drawdown | 34.41 | |||
| Value At Risk | (8.51) | |||
| Potential Upside | 8.21 |
CytomX Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CytomX Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CytomX Therapeutics' standard deviation. In reality, there are many statistical measures that can use CytomX Therapeutics historical prices to predict the future CytomX Therapeutics' volatility.| Risk Adjusted Performance | 0.1076 | |||
| Jensen Alpha | 0.5848 | |||
| Total Risk Alpha | 0.1301 | |||
| Sortino Ratio | 0.128 | |||
| Treynor Ratio | 0.4568 |
CytomX Therapeutics February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1076 | |||
| Market Risk Adjusted Performance | 0.4668 | |||
| Mean Deviation | 3.93 | |||
| Semi Deviation | 4.4 | |||
| Downside Deviation | 4.91 | |||
| Coefficient Of Variation | 814.17 | |||
| Standard Deviation | 5.85 | |||
| Variance | 34.2 | |||
| Information Ratio | 0.1075 | |||
| Jensen Alpha | 0.5848 | |||
| Total Risk Alpha | 0.1301 | |||
| Sortino Ratio | 0.128 | |||
| Treynor Ratio | 0.4568 | |||
| Maximum Drawdown | 34.41 | |||
| Value At Risk | (8.51) | |||
| Potential Upside | 8.21 | |||
| Downside Variance | 24.13 | |||
| Semi Variance | 19.4 | |||
| Expected Short fall | (4.49) | |||
| Skewness | 1.23 | |||
| Kurtosis | 5.9 |
CytomX Therapeutics Backtested Returns
CytomX Therapeutics appears to be moderately volatile, given 3 months investment horizon. CytomX Therapeutics secures Sharpe Ratio (or Efficiency) of 0.12, which signifies that the company had a 0.12 % return per unit of risk over the last 3 months. By analyzing CytomX Therapeutics' technical indicators, you can evaluate if the expected return of 0.62% is justified by implied risk. Please makes use of CytomX Therapeutics' Downside Deviation of 4.91, risk adjusted performance of 0.1076, and Mean Deviation of 3.93 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, CytomX Therapeutics holds a performance score of 9. The firm shows a Beta (market volatility) of 1.55, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, CytomX Therapeutics will likely underperform. Please check CytomX Therapeutics' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether CytomX Therapeutics' price patterns will revert.
Auto-correlation | 0.25 |
Poor predictability
CytomX Therapeutics has poor predictability. Overlapping area represents the amount of predictability between CytomX Therapeutics time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CytomX Therapeutics price movement. The serial correlation of 0.25 indicates that over 25.0% of current CytomX Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.25 | |
| Spearman Rank Test | 0.28 | |
| Residual Average | 0.0 | |
| Price Variance | 0.53 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.